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RESULTS: The percentage of successful intercourse with
Viagra treatment was 72% while with the Muse treat-
ment, it was 63%. The incremental cost-effectiveness ra-
tio was calculated to be $628 per successful intercourse. 
CONCLUSION: Our results indicate that one additional
successful intercourse would cost $628 more when switch-
ing from Muse to Viagra. If using an average cut-off ratio
of $50 per successful event which was estimated directly
from a group of patients’ preferences as a willingness-to-
pay measure, we concluded that Viagra could not be con-
sidered to be cost-effective compared to Muse in the
treatment of male erectile dysfunction.
PWM9
ECONOMIC EVALUATION IN REAL-LIFE 
SETTING OF ALPHA-BLOCKERS VERSUS 
FINASTERIDE VERSUS SERENOA REPENS
IN THE TREATMENT OF BENIGN
PROSTATIC HYPERPLASIA
Schmitt C1, Aussage P1, Berdeaux G2
1ARCOS, Issy-les-Moulineaux, France; 2Pierre Fabre 
Médicament, Boulogne-Billancourt, France
OBJECTIVE: To identify prescription patterns and costs
of benign prostatic hyperplasia (BPH) therapy in a real-
life setting. 
METHODS: Records from the French primary care data-
base Thales were screened to identify patients who initi-
ated a therapy with either -blockers (A) [alfuzosin, tam-
sulosin, terazosin] or finasteride (F), or a lipido-sterolic
extract of Serenoa repens (Px), between June 1996 and
May 1997 and who were followed up for at least 12
months. Patients with a diagnosis of prostatic cancer were
excluded. Endpoints were: 1-year BPH related costs, con-
comitant medication costs and total healthcare costs ac-
cording to the French National Health System. In order
to adjust for differences of socioeconomic and clinical
characteristics between treatment groups, endpoints were
analyzed using the propensity score method. 
RESULTS: 601 patients were identified in group A, 264 in
group F, and 315 in group Px. The median age was 67
years. Groups were unbalanced as to age (P  0.01), hy-
pertension (P  0.05), and urological troubles (P  0.05):
A were prescribed to younger patients with less hyperten-
sion, while F was prescribed to patients with less urologi-
cal disturbances. Unadjusted annual total healthcare costs
per patient were $1130 for group A, $1360 for group F,
and $1120 for group Px. Difference between A and Px re-
mained after adjustment ($36), due to a lower price of Px
and to reduced concomitant prescription costs. Difference
between F and Px also remained after adjustment ($242),
due to the previous reasons but also to a shorter treatment
duration. 
CONCLUSION: In real-life clinical practice, annual total
healthcare costs were lower when initiating a treatment
for BPH with Serenoa repens than with finasteride and
-blockers.
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The role of quality of life information in influencing man-
aged care decision-making in the United States is not well
understood. Previous research has suggested that efficacy,
safety, and cost-effectiveness information is viewed with
the highest level of importance and quality of life informa-
tion is viewed as more supplemental in nature. 
OBJECTIVE: The purpose of this study was to gain an
understanding of how decision-makers view quality of
life information. In particular, 1) the current and future
use of the information was examined, 2) the usefulness
and understanding of several types of QoL instruments,
and 3) the perceived weaknesses and strengths of quality
of life research. 
METHODS: Forty-one pharmacy and managed care di-
rectors completed a questionnaire by telephone to elicit
their attitudes on QoL research in managed care deci-
sion-making. 
RESULTS: Respondents felt that disease-specific quality of
life instruments were most useful (mean rank of 1.90 on a
5-point scale; 1  most useful), patient utility measures
ranked 3.10 and generic quality of life measures 3.83. Re-
spondents were asked their level of familiarity (5-point
Likert scale) with 11 common, disease-specific and generic
measures. They were most familiar with the SF-36 (mean
rank 3.17) and least familiar with the EuroQoL (mean
rank 1.34). Respondents felt that the results of QoL evalu-
ations could not be generalized (51.2%) and suffered from
too many assumptions (53.7%). Most respondents (52.7%)
felt that the main strength of QoL studies was that they
consider the perspective of the patient. 
CONCLUSIONS: Familiarity with QoL research and in-
struments by MCO decision-makers is relatively low, and
research in the area suffers from broad acceptability. Fu-
ture work should be conducted to educate MCOs on the
usefulness of QoL evaluations.
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Healthcare providers are under increasing pressure to doc-
ument their outcomes to managed care organizations, em-
